* H1 group sales 20.1 mln pounds vs 22.9 mln year ago
* Operating profit 0.2 mln pounds vs 2.0 mln
* Half-year results hit by drop in Cormet hip sales
(Adds details, background)
First-half sales and profits fell at British medical technology group Corin (COCRG.L), hit by weak demand for its Cormet hip resurfacing product and lower sales to U.S. orthopaedics giant Stryker (SYK.N).
Sales in the six months to June 30 were 20.1 million pounds ($33.2 million), down from 22.9 million a year ago, although still above the 19.4 million predicted by analysts at brokerage Nomura Code.
With operating profit of just 200,000 pounds, down from 2.0 million in the first half of 2008, Corin made a loss per share of 0.16 pence against earnings a year earlier of 2.13p.
Despite the problems with Cormet, chief executive Peter Huntley said the company had achieved notable non-U.S. revenue growth and it remained on course to achieve its medium-term targets. ($1=.6059 Pound) (Reporting by Ben Hirschler; Editing by Jon Loades-Carter)